Jessica M. Donigan, MD; Mark A. Hyde, MMS, PA-C; David E. Goldgar, PhD; et al.
free access
JAMA Dermatol. 2018;154(8):885-889. doi:10.1001/jamadermatol.2018.0530
This medical record review examines the rate of recurrence of lentigo maligna in patients treated with neoadjuvant topical imiquimod, 5%, cream prior to conservatively staged excisions.
Jungyoon Ohn, MD; Gwanghyun Jo, MD; Youngjoo Cho, PhD; et al.
free access
JAMA Dermatol. 2018;154(8):890-896. doi:10.1001/jamadermatol.2018.1372
This cohort study identifies the dermoscopic features of subungual melanoma in situ in a Korean population and assesses a predictive scoring model that distinguishes the diagnosis of subungual melanoma in situ from longitudinal melanonychia in patients with pigmented nails.
Kasey L. Morris, PhD; Frank M. Perna, EdD, PhD
free access
JAMA Dermatol. 2018;154(8):897-902. doi:10.1001/jamadermatol.2018.1646
This cross-sectional national survey assesses whether decision-based modeling can identify patterns of sun-protective behaviors and sun sensitivity associated with the likelihood of sunburn among US adults.
Eric L. Simpson, MD; Emma Guttman-Yassky, MD, PhD; David J. Margolis, MD, PhD; et al.
open access
has audio
JAMA Dermatol. 2018;154(8):903-912. doi:10.1001/jamadermatol.2018.1572
This cross-sectional study examines the association of atopic dermatitis severity and disease control with the patient-reported disease burden in clinical practice.
-
Audio Author Interview:
Association of Inadequately Controlled Disease With Patient-reported Disease Burden in Atopic Dermatitis
Marina Danilenko, PhD; Elaine Stamp, MSc; Deborah D. Stocken, PhD; et al.
open access
JAMA Dermatol. 2018;154(8):913-921. doi:10.1001/jamadermatol.2018.1610
This phase 2 randomized clinical trial investigates if topical targeting of topical tropomyosin receptor kinase (TRK) with an inhibitor, pegcantratinib, is safe and efficacious in treating tumors in patients with CYLD cutaneous syndrome.